News
Decision made concerning rights issue of convertible bonds
At the meeting of the Board of Directors in PharmaLundensis AB (publ) today, Thursday 4 April 2019, and with the support of the authorization of the Annual General Meeting held on 15 June 2018, it was resolved that the Company shall issue a convertible loan of nominally no more than SEK 4,732,500 through the issue of a maximum of 315,500 convertible bonds with preferential rights for existing shareholders. Each existing share in the Company on the record date of 11 April 2019 shall give entitlement to one subscription right, and 71 subscription rights shall give entitlement to subscription of a convertible bond at a subscription price of SEK 15. The subscription period is 15-30 April 2019. The loan shall have an annual interest rate of 13 percent from 15 May 2019 to 15 May 2025, and shall be paid in full after the due date. Thus 208.2% of the invested amount shall be repaid with interest on interest. The convertible bond will not be listed on any marketplace. At full subscription, PharmaLundensis will receive approximately SEK 4.73 million before issue costs. Issue costs are estimated to amount to approximately SEK 400,000.
